This approach has yielded significant clinical benefits in malignancies such as chronic myeloid leukemia (CML) with BCR-ABL1 fusion and NTRK fusion-positive tumors, where targeted monotherapies have demonstrated remarkable efficacy [1,2]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.